Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2012 2
2013 2
2015 2
2016 1
2017 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Prioritizing polio.
Rath B, Ali M, Elemuwa C, Maurer W, Bouder F, Mworozi E, Diedrich S, Khamesipour A, Chitwood I, Kochhar S; Vienna Vaccine Safety Initiative. Rath B, et al. Among authors: bouder f. Expert Rev Vaccines. 2012 Dec;11(12):1389-92. doi: 10.1586/erv.12.128. Expert Rev Vaccines. 2012. PMID: 23252381 No abstract available.
Pharmaceutical Benefit-Risk Communication Tools: A Review of the Literature.
Way D, Blazsin H, Löfstedt R, Bouder F. Way D, et al. Among authors: bouder f. Drug Saf. 2017 Jan;40(1):15-36. doi: 10.1007/s40264-016-0466-1. Drug Saf. 2017. PMID: 27743334 Review.
Risk communication of vaccines: challenges in the post-trust environment.
Bouder F. Bouder F. Curr Drug Saf. 2015;10(1):9-15. doi: 10.2174/157488631001150407103916. Curr Drug Saf. 2015. PMID: 25859669 Review.
Transparency and the Food and Drug Administration--a quantitative study.
Lofstedt R, Bouder F, Chakraborty S. Lofstedt R, et al. Among authors: bouder f. J Health Commun. 2013;18(4):391-6. doi: 10.1080/10810730.2012.696229. Epub 2012 Nov 6. J Health Commun. 2013. PMID: 23130648 Review.
The importance of the patient voice in vaccination and vaccine safety-are we listening?
Holt D, Bouder F, Elemuwa C, Gaedicke G, Khamesipour A, Kisler B, Kochhar S, Kutalek R, Maurer W, Obermeier P, Seeber L, Trusko B, Gould S, Rath B. Holt D, et al. Among authors: bouder f. Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S146-S153. doi: 10.1016/j.cmi.2016.09.027. Epub 2016 Dec 6. Clin Microbiol Infect. 2016. PMID: 27939015 Free article.
Transparency in Europe: A Quantitative Study.
Bouder F, Way D, Löfstedt R, Evensen D. Bouder F, et al. Risk Anal. 2015 Jul;35(7):1210-29. doi: 10.1111/risa.12386. Epub 2015 May 1. Risk Anal. 2015. PMID: 25931009
The future of risk communication and the role of the pharmaceutical industry.
Chakraborty S, Bouder F. Chakraborty S, et al. Among authors: bouder f. Curr Drug Saf. 2013 Feb;8(1):4-10. doi: 10.2174/1574886311308010002. Curr Drug Saf. 2013. PMID: 23656442
Regulating impurities in pharmaceutical products: a tolerability of risk approach?
Bouder F. Bouder F. Expert Rev Clin Pharmacol. 2008 Mar;1(2):241-50. doi: 10.1586/17512433.1.2.241. Expert Rev Clin Pharmacol. 2008. PMID: 24422649
Tolerability of risk approach and the management of pharmaceutical risks.
Bouder F, Löfstedt R. Bouder F, et al. Expert Rev Clin Pharmacol. 2008 Mar;1(2):187-90. doi: 10.1586/17512433.1.2.187. Expert Rev Clin Pharmacol. 2008. PMID: 24422643 No abstract available.